Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma

Jilkova Zuzana Macek; Kuyucu Aya Zeybek; Kurma Keerthi; Tayebeh Amad Pour Seyedeh; Decaens Thomas

首页> 外文期刊>Hepatology: Official Journal of the American Association for the Study of Liver Diseases >Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma

【24h】

Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma

机译：AKT抑制剂ARQ 092和索拉非尼与肝细胞癌肝硬化大鼠模型中的组合治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Hepatology: Official Journal of the American Association for the Study of Liver Diseases》 |2016年第s1期|共1页
作者
Jilkova Zuzana Macek; Kuyucu Aya Zeybek; Kurma Keerthi; Tayebeh Amad Pour Seyedeh; Decaens Thomas;
展开▼
作者单位

INSERM U1209 Grenoble France;

INSERM U1209 Grenoble France;

INSERM U1209 Grenoble France;

INSERM U1209 Grenoble France;

CHU Grenoble Alpes Grenoble France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma [J] . Jilkova Zuzana Macek, Kuyucu Aya Zeybek, Kurma Keerthi, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：AKT抑制剂ARQ 092和索拉非尼与肝细胞癌肝硬化大鼠模型中的组合治疗
2. The synergistic anti-proliferative effect of combining the FGFR inhibitor, ARQ 087 with the AKT inhibitor, ARQ 092 in human cancer cell lines and PDX models [J] . Marchlik E., Yu Y., Chiesa E., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014,第Suppla6期

机译：FGFR抑制剂ARQ 087与AKT抑制剂ARQ 092联合在人癌细胞系和PDX模型中的协同抗增殖作用
3. Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report [J] . Susanne Gahr, Till Wissniowski, Steffen Zopf, Journal of Cancer . 2012,第16期

机译：脱乙酰基酶抑制剂Panobinostat和多激酶抑制剂索拉非尼联合治疗转移性肝细胞癌的研究-潜在的分子机制和第一例报道
4. Photoacoustic-ultrasonic imaging biomarkers for treatment-response assessment of sorafenib in a rat model of hepatocellular carcinoma [C] . Houra Taghavi, Nina Munoz, Mohamed Naser, IEEE International Ultrasonics Symposium . 2017

机译：光声-超声成像生物标记物用于索拉非尼在肝细胞癌大鼠模型中的治疗反应评估
5. Poly(lactide-co-glycolide) Microspheres for Localized, Magnetic Resonance Imaging Monitored, Transcatheter Delivery of Sorafenib to Hepatocellular Carcinoma. [D] . Chen, Jeane. 2015

机译：聚（丙交酯-共-乙交酯）微球体用于局部监测，磁共振成像监测，索拉非尼经导管输送至肝细胞癌。
6. Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma [O] . Zuzana Macek Jilkova, Ayca Zeybek Kuyucu, Keerthi Kurma, 2018

机译：AKT抑制剂ARQ 092与索拉非尼联合可增强肝硬化大鼠肝癌模型的肿瘤进展抑制作用
7. Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma [O] . Gaël S. Roth, Zuzana Macek Jilkova, Ayca Zeybek Kuyucu, 2017

机译：与肝细胞癌肝硬化大鼠模型中索拉非尼与索拉非尼相比，AKT抑制剂ARQ 092的疗效

Combination treatment by AKT inhibitor ARQ 092 and Sorafenib in a cirrhotic rat model with hepatocellular carcinoma

著录项

相似文献

相关主题

期刊订阅